Leonard S. Jacob Sells 92,078 Shares of Antares Pharma Inc (NASDAQ:ATRS) Stock

Antares Pharma Inc (NASDAQ:ATRS) Director Leonard S. Jacob sold 92,078 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $3.00, for a total value of $276,234.00. Following the completion of the sale, the director now directly owns 301,970 shares of the company’s stock, valued at $905,910. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of NASDAQ:ATRS traded up $0.06 during trading on Friday, hitting $3.04. 1,294,284 shares of the company traded hands, compared to its average volume of 748,548. The firm has a market capitalization of $494.36 million, a PE ratio of -76.00 and a beta of 1.03. Antares Pharma Inc has a one year low of $2.16 and a one year high of $3.96. The company has a current ratio of 2.62, a quick ratio of 2.20 and a debt-to-equity ratio of 0.57.

Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The company had revenue of $23.29 million during the quarter, compared to analyst estimates of $17.46 million. Antares Pharma had a negative return on equity of 19.98% and a negative net margin of 7.91%. As a group, analysts predict that Antares Pharma Inc will post -0.06 EPS for the current fiscal year.

A number of brokerages have recently commented on ATRS. Cowen began coverage on Antares Pharma in a research report on Monday, February 25th. They issued an “outperform” rating and a $1.99 price objective for the company. Raymond James boosted their price target on Antares Pharma from $5.25 to $5.65 and gave the company a “strong-buy” rating in a research report on Monday, March 4th. TheStreet raised Antares Pharma from a “d” rating to a “c” rating in a research report on Friday, March 1st. Finally, BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $4.83.

A number of hedge funds have recently modified their holdings of ATRS. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Antares Pharma during the 4th quarter valued at $31,000. Foundations Investment Advisors LLC acquired a new stake in shares of Antares Pharma during the 4th quarter valued at $42,000. Virtu Financial LLC acquired a new stake in shares of Antares Pharma during the 4th quarter valued at $45,000. Enterprise Bank & Trust Co acquired a new stake in shares of Antares Pharma during the 1st quarter valued at $45,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Antares Pharma during the 4th quarter valued at $51,000. 41.25% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Leonard S. Jacob Sells 92,078 Shares of Antares Pharma Inc (NASDAQ:ATRS) Stock” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/05/insider-selling-antares-pharma-inc-atrs-director-sells-276234-00-in-stock.html.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: What is intrinsic value?

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.